Clinical and regulatory intelligence for Retinal Diseases with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 2

Relevant assets

AI →

Vabysmo →

Relevant companies

biotech firms in ophthalmology →

L-ORD →

Roche →

Recent signals(3)

ClinicalJuly 27, 2026

AI Study to Enhance Diagnostic Accuracy in Retinal Imaging

A prospective observational study will assess the impact of AI on ophthalmologists' diagnostic performance using ultra-widefield retinal images.

ClinicalJune 20, 2026

Study Initiated to Collect Samples for Eye Disease Research

The National Eye Institute is conducting a study to collect biological samples from individuals with Best disease, L-ORD, and AMD to facilitate research on these retinal conditions.

StrategyJune 17, 2026

Roche Presents New Data on Vabysmo and Susvimo at ARVO 2026

New real-world data confirm Vabysmo's effectiveness in drying the retina for nAMD and DME, while Susvimo shows potential for sustained disease control.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Ophthalmology →

Retinal Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.